Valneva vola a Parigi, vaccino Lyme supera primo step procedurale Ema

European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application - Pfizer (NYSE:PFE), V

Valneva (VALN) stock surges after EMA validates MAA for Lyme disease vaccine candidate developed with Pfizer (PFE). Phase 3 trial showed efficacy and no safety concerns, pending regulatory approval.